Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares the effectiveness of greater occipital nerve blockade and sphenopalatine ganglion blockade in reducing headache intensity, duration, frequency, and disability in patients with episodic migraine.
Migraine is a chronic neurological disorder characterized by recurrent headaches, affecting millions globally. Peripheral nerve blocks such as Greater Occipital Nerve (GON) and Sphenopalatine Ganglion (SPG) blockade have emerged as promising non-pharmacologic treatments.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Greater occipital nerve blockade group | Experimental | Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process. |
|
| Sphenopalatine ganglion blockade group | Experimental | Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Greater occipital nerve blockade | Other | Patients will receive greater occipital nerve blockade using 2 mL of 2% lidocaine at the medial one-third of the line between the occipital protuberance and mastoid process. |
| Measure | Description | Time Frame |
|---|---|---|
| Degree of headache intensity | Reduction in headache intensity will be recorded using numeric rating scale (NRS). Each patient will be instructed about pain assessment with NRS score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). | 3 months post-procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Migraine disability assessment score | The migraine disability assessment scores are as follows: little or no disability, 5 to 10; moderate disability, 1 to 20; and severe disability, more than 20. | 3 months post-procedure |
| Headache duration |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| New Valley University | New Valley | New Valley Governorate | 72511 | Egypt |
The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
After the end of study for one year.
The data will be available upon a reasonable request from the corresponding author.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sphenopalatine ganglion blockade | Other | Patients will receive greater sphenopalatine ganglion blockade using 2 mL of 2% lidocaine using a transnasal approach with a cotton swab inserted along the superior middle turbinate to the posterior nasopharyngeal wall. |
|
Headache duration will be recorded.
| 3 months post-procedure |
| Headache frequency | Headache frequency will be recorded. | 3 months post-procedure |